These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
ICMR will continue to track trends in HMPV circulation throughout the year
2.92 acre facility will combine tradition and innovation, offering new opportunities for holistic healing, specialized clinics, and skill development to be constructed at a cost of around Rs. 185 crore
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The order, part of an international framework agreement is to be executed between February to April, 2025
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Subscribe To Our Newsletter & Stay Updated
